Previous 10 | Next 10 |
Directly or indirectly, peroxynitrite is responsible for much of the damage done to the brain in Alzheimer's disease. As a sigma-1 agonist, blarcamesine limits peroxynitrite formation by inhibiting intracellular calcium release. Blarcamesine likely scavenges peroxynitrite. I...
Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...
Alector press release (NASDAQ:ALEC): Q1 GAAP EPS of -$0.54 misses by $1.22. Revenue of $24.5M (+496.1% Y/Y). $868.6M in cash, cash equivalents, and marketable securities provide runway into mid-2024. For further details see: Alector GAAP EPS of -$0.54 misses by $1.22, revenue of $2...
Data from INFRONT-2 Phase 2 clinical trial showed that FTD-C9orf72 patients treated with AL001 (latozinemab) demonstrated a trend towards an annual delay in disease progression of approximately 54 percent relative to the ALLFTD matched control cohort INFRONT-2 FTD-C9orf72 cohort...
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on&...
Oxidative stress contributes to the formation of misfolded amyloid and tau proteins and to neuroinflammation all of which can further increase oxidative stress. Drugs that target pro-inflammatory cytokines such as INmune Bio's XPro1595 and Montelukast are likely too specific and too l...
Alector has a novel approach to neurodegenerative diseases. Alector thinks that the immune system gone wrong causes those diseases. A phase 3 trial with data readout next year may prove them right. For further details see: Alector: Expect Phase 3 Data Next Year
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia among the elderly, accounting for between 60% and 80...
Alector (NASDAQ:ALEC), a clinical stage-biotech focused on neurodegenerative diseases, announced the appointment of Gary Romano as its Chief Medical Officer on Tuesday. Dr. Romano will report to Sara Kenkare-Mitra, the company’s Head of R&D, and his appointment takes effect on May ...
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead th...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...